These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31753774)

  • 1. Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years.
    Nakamura Y; Okubo M; Furuta Y; Tokida M; Ichikawa K; Ohsaka A
    Transfus Apher Sci; 2019 Dec; 58(6):102664. PubMed ID: 31753774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
    Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
    Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
    Okubo M; Furuta Y; Nakamura Y; Osawa T; Tada N; Sawada T; Yamatoya K; Sekiguchi Y; Araki Y; Miyake K; Noguchi M; Komatsu N; Ohsaka A
    Ther Apher Dial; 2021 Oct; 25(5):687-696. PubMed ID: 33325621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new protocol for improving efficiency of autologous peripheral blood stem cell collection in patients with high white blood cell counts.
    Boehlen R; Fernandez P; Bargetzi M; Sigle JP
    J Clin Apher; 2020 Jun; 35(3):217-223. PubMed ID: 32304598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.
    Gutiérrez-Aguirre CH; Alvarado-Navarro DM; Palomares-Leal A; Mejía-Jaramillo G; Salazar-Riojas R; León AG; Colunga-Pedraza PR; Sotomayor-Duque G; Jaime-Pérez JC; Cantú-Rodríguez OG; Del Carmen Tarín-Arzaga L; Flores-Jiménez JA; Gómez-Almaguer D
    Transfusion; 2019 Dec; 59(12):3721-3726. PubMed ID: 31618456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of just-in-time plerixafor rescue for Hodgkin's lymphoma patients with poor peripheral blood stem cell mobilization.
    Yuan S; Nademanee A; Kaniewski M; Palmer J; Shayani S; Wang S
    Transfusion; 2014 Aug; 54(8):2015-21. PubMed ID: 24660786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of plerixafor in autologous peripheral blood stem cell collection].
    Yogo T; Tsukada N; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Okazuka K; Ishida T; Suzuki K
    Rinsho Ketsueki; 2019; 60(3):165-170. PubMed ID: 31068511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield.
    Villa CH; Shore T; Van Besien K; Cushing M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1867-75. PubMed ID: 22796644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients.
    Kong JH; Hu Y; Kong SY; Lee SN; Eom HS; Lee H; Lee E; Shim H
    J Clin Apher; 2021 Feb; 36(1):135-142. PubMed ID: 33247855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
    Micallef IN; Sinha S; Gastineau DA; Wolf R; Inwards DJ; Gertz MA; Hayman SR; Hogan WJ; Johnston PB; Lacy MQ; Ansell SM; Buadi F; Dingli D; Dispenzieri A; Litzow MR; Porrata LF; Winters JL; Kumar S
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):87-93. PubMed ID: 22922211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
    Lefrère F; Mauge L; Réa D; Ribeil JA; Dal Cortivo L; Brignier AC; Aoun C; Larghéro J; Cavazzana-Calvo M; Micléa JM
    Transfusion; 2013 Mar; 53(3):564-9. PubMed ID: 22725259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
    Teusink A; Pinkard S; Davies S; Mueller M; Jodele S
    Transfusion; 2016 Jun; 56(6):1402-5. PubMed ID: 27079854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of CD34(+) cell yield in hematopoietic cell products from children by peripheral blood CD34(+) cell counts.
    Rujkijyanont P; Hipps J; Gan K; Yang J; Wang C; Geiger TL; Eldridge PW; Leung W
    Cytotherapy; 2012 Apr; 14(4):473-82. PubMed ID: 22420835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.
    Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH
    Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
    Zhuang L; Boriboonnangkul P; Wang S; Yuan S
    Transfusion; 2020 Jun; 60(6):1253-1259. PubMed ID: 32483875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
    Zhuang L; Lauro D; Wang S; Yuan S
    J Clin Apher; 2022 Aug; 37(4):388-394. PubMed ID: 35633513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.